Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion

Stock Track05-06

Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.

The sharp rise follows the company's release of first-quarter 2026 financial results, which showed a smaller-than-expected loss and revenue that surpassed analyst forecasts. Madrigal reported a quarterly loss of $3.25 per share, beating the consensus estimate of a $3.60 loss, while sales of $311.34 million exceeded expectations of $302.27 million.

Investor sentiment was further bolstered by news that Madrigal secured an exclusive worldwide license for ARO-PNPLA3, a clinical-stage RNAi therapy for MASH, expanding its pipeline beyond its foundational drug Rezdiffra. Additionally, HC Wainwright & Co. maintained its $620 price target on the stock, adding to the positive outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153136429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153136429","market":"nz","top_or_hot":-1,"title":"Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion","media":"Stock Track","content":"<p>Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.</p><p>The sharp rise follows the company's release of first-quarter 2026 financial results, which showed a smaller-than-expected loss and revenue that surpassed analyst forecasts. Madrigal reported a quarterly loss of $3.25 per share, beating the consensus estimate of a $3.60 loss, while sales of $311.34 million exceeded expectations of $302.27 million.</p><p>Investor sentiment was further bolstered by news that Madrigal secured an exclusive worldwide license for ARO-PNPLA3, a clinical-stage RNAi therapy for MASH, expanding its pipeline beyond its foundational drug Rezdiffra. Additionally, HC Wainwright & Co. maintained its $620 price target on the stock, adding to the positive outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.</p><p>The sharp rise follows the company's release of first-quarter 2026 financial results, which showed a smaller-than-expected loss and revenue that surpassed analyst forecasts. Madrigal reported a quarterly loss of $3.25 per share, beating the consensus estimate of a $3.60 loss, while sales of $311.34 million exceeded expectations of $302.27 million.</p><p>Investor sentiment was further bolstered by news that Madrigal secured an exclusive worldwide license for ARO-PNPLA3, a clinical-stage RNAi therapy for MASH, expanding its pipeline beyond its foundational drug Rezdiffra. Additionally, HC Wainwright & Co. maintained its $620 price target on the stock, adding to the positive outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1153136429","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153136429","pubTimestamp":1778076344,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.The sharp rise follows the company's release of first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"个股追踪|Madrigal Pharmaceuticals盘前大涨7.44%因Q1盈利强劲及管线扩张","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals' stock surged 7.44% during pre-market trading on Wednesday, reflecting significant investor optimism.The sharp rise follows the company's release of first-quarter 2026 financial results, which showed a smaller-than-expected loss and revenue that surpassed analyst forecasts. Madrigal reported a quarterly loss of $3.25 per share, beating the consensus estimate of a $3.60 loss, while sales of $311.34 million exceeded expectations of $302.27 million.Investor sentiment was further bolstered by news that Madrigal secured an exclusive worldwide license for ARO-PNPLA3, a clinical-stage RNAi therapy for MASH, expanding its pipeline beyond its foundational drug Rezdiffra. Additionally, HC Wainwright & Co. maintained its $620 price target on the stock, adding to the positive outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153136429","isCrawlerRequest":true}